Roche Polska

What Roche Polska does

Roche Polska Sp. z o.o. is the Polish operating subsidiary of F. Hoffmann-La Roche Ltd, the Swiss multinational pharmaceutical group founded in Basel in 1896. The Polish operations were established in 1999 as a regional clinical trials center for Central Europe and are headquartered in Warsaw at ul. Domaniewska 28. The legal structure includes two additional wholly-owned operating subsidiaries: Roche Diagnostics Polska Sp. z o.o. and Roche Diabetes Care Polska Sp. z o.o., together employing approximately 1,264 staff (2019 headcount: 895 pharmaceutical, 274 diagnostics, 95 diabetes care).

The company operates across three interconnected pillars: Pharmaceuticals (innovative prescription medicines in oncology, neurology, ophthalmology, hematology, and nephrology), Diagnostics (in vitro diagnostics and medical devices via the Roche Diagnostics Polska subsidiary), and Digital Health (including the navify Portal, the patient-facing wiedzapacjenta.roche.pl, and the restricted-access physician portal dlalekarzy.roche.pl). In clinical research, Roche Polska is the largest clinical trials operator within the Roche Group globally by number of trials and centers, has run 350+ trials since 1999, enrolled 22,000+ patients, and ranked #11 globally in commercial clinical trial market share. Reported 2019 total revenue was 2.47 billion PLN, comprising pharmaceutical sales, 821.8M PLN of IT services, 108.1M PLN of clinical trial services, and 6.3M PLN of procurement hub services. R&D investments in Poland that year reached 887.7M PLN, exceeding reimbursement-derived sales by 60M PLN.

The business model is sales-led, primarily through a medical representative field force engaging with physicians, hospitals, and clinical trial centers, complemented by dedicated digital portals and a network of licensed pharmaceutical wholesalers and pharmacies. Beyond the regulated pharma-distribution core, Roche Polska runs ecosystem- and talent-building initiatives: the Science-Industry Center with Centrum Onkologii-Instytut (founded 2016), the BioMed Leaders Academy with the University of Warsaw Incubator (since 2017), the Data Science in Medicine postgraduate program with Poznań Medical University (since 2022), and most recently the Poland Healthcare Datathon co-organized with MIT Critical Data, GUMed, and UCK Gdańsk. Forward positioning is anchored by a January 2026 letter of intent with Poland's Medical Research Agency to anchor the Warsaw Health Innovation Hub.

Name

Roche Polska

Legal name

Roche Polska Sp. z o.o.

Website

https://roche.pl

Company type

Private

Founded year

1999

Operating status

Operating

Short description

Roche Polska is the Polish subsidiary of Swiss pharmaceutical group F. Hoffmann-La Roche, developing and commercializing prescription medicines, diagnostics, and digital health products while serving as the group's #1 regional clinical trials hub for Central Europe.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Prescription pharmaceuticals
• In vitro diagnostics
• Clinical research services
• Oncology therapeutics
• Digital health platforms

Headquarters

HQ city

Warszawa

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Products (Prescription Medicines): Roche Polska develops and commercializes innovative prescription medicines across oncology, neurology, ophthalmology, hematology, and nephrology. Products are sold through the healthcare system under regulated reimbursement frameworks. Revenue from pharmaceutical sales in Poland is partially offset by investments in R&D exceeding sales figures.
2. Clinical Research Services: Roche Polska conducts clinical trials in Poland as part of global Roche research programs. Clinical operations span Phase I through Phase IV studies across multiple therapeutic areas. Poland serves as a regional clinical trials hub for Central Europe.
3. Diagnostic Solutions: Roche Diagnostics Polska and Roche Diabetes Care Polska (separate legal entities) commercialize diagnostic products, in vitro diagnostics, and medical devices for diabetes therapy in Poland.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Roche Polska develops, supplies and commercializes innovative prescription medicines across oncology, neurology, ophthalmology, hematology, and nephrology in Poland, distributed through licensed wholesalers and pharmacies. Through its wholly-owned subsidiaries Roche Diagnostics Polska and Roche Diabetes Care Polska, it markets in vitro diagnostics and medical devices for diabetes therapy. The company also operates a Phase I–IV clinical research program across 152 Polish centers and provides digital health platforms (Wiedza Pacjenta, Dla Lekarzy, navify) for patients, physicians, and healthcare organizations.

Product overview

Roche Polska operates three interconnected business pillars: Pharmaceutical Products (innovative medicines across oncology, neurology, ophthalmology, and other therapeutic areas), Diagnostic Solutions (tests for detection, diagnosis, and monitoring), and Digital Health Solutions (including patient-facing portals like Wiedza Pacjenta, physician portal dla lekarzy, and analytical platforms like navify Portal). The portfolio also includes clinical trial services, personalized medicine approaches, and innovation initiatives through Innolab. The company serves patients, healthcare professionals, and healthcare institutions through both traditional pharmaceutical/diagnostic products and digital platforms.

Differentiator

Problem solved

Functional benefit

Brands

• Wiedza Pacjenta by Roche: Patient knowledge portal providing information about clinical trials, disease descriptions, and medical research for patients, families, caregivers, and physicians
• Dla Lekarzy

Products and services

• Pharmaceutical Products (Produkty lecznicze) Innovative prescription medicines for prevention, treatment and monitoring across oncology, neurology, ophthalmology, hematology, and nephrology, developed over more than 50 years of Roche research expertise and sold to physicians and hospitals in Poland.
• Diagnostic Solutions (Rozwiązania diagnostyczne) In vitro diagnostics, medical devices, and diabetes-care products and services marketed in Poland through wholly-owned subsidiaries Roche Diagnostics Polska Sp. z o.o. and Roche Diabetes Care Polska Sp. z o.o., serving diagnostic laboratories, hospitals, and patients with diabetes.
• Clinical Trials (Badania Kliniczne) Comprehensive Phase I through Phase IV clinical research services delivered through 152 Polish centers, providing Polish patients access to innovative therapies and supporting Roche's global evidence-based medicine development across multiple therapeutic areas.
• Wiedza Pacjenta Portal (Patient Knowledge Portal) Digital information resource providing patients, families, caregivers, and physicians with disease descriptions, medical research information, and a clinical trial search tool by disease area and location.
• Portal Dla Lekarzy (Physician Portal) Restricted-access digital portal for physicians and pharmaceutical distribution professionals delivering Roche medication information, professional medical news, and continuing medical education materials.
• navify Portal Clinical data analytics and workflow management platform enabling healthcare organizations to derive insights from operational data, manage digital pathology workflows, and streamline healthcare processes.
• Data Science in Medicine Postgraduate Program Postgraduate educational program combining clinical knowledge with data analytics, Python programming, machine learning, NLP, and computer vision for healthcare applications, delivered jointly with Poznań Medical University.

Quantifiable outcome

• Over 350 clinical trials conducted in Poland since 1999, with 22,000+ patients enrolled
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability7 records

Feature5 records

Partnerships

16 partnerships are on record, tiered core, minor and secondary.

• Agencja Badań Medycznych (Medical Research Agency, Poland)coreStrategic or Co-development Partner · 22 January 2026Roche Polska signed a letter of intent with the Medical Research Agency for continued collaboration under Warsaw Health Innovation Hub. Prof. Wojciech Fendler (ABM President) and Ehab Youssef (Head of Europe Area North, Roche) participated in the signing. The partnership aims to strengthen Poland's position in clinical research and health innovation.
• Novartis PolandminorGTM or Marketing Partner · 1 January 2026Co-initiator of 'Urlop na profilaktykę – 8h na badania' (Preventive Leave initiative) within Polsko-Szwajcarska Izba Gospodarcza (Polish-Swiss Chamber of Commerce), enabling employees to take 8 hours for health screenings.
• Sandoz PolskaminorGTM or Marketing Partner · 1 January 2026Co-initiator of 'Urlop na profilaktykę – 8h na badania' (Preventive Leave initiative) within Polsko-Szwajcarska Izba Gospodarcza.
• Girls Future Ready FoundationminorStrategic or Co-development Partner · 1 January 2026HerStory initiative — joint project between Roche Polska and Girls Future Ready, connecting female leaders across industries with young women at the start of their careers. Led by female Roche executives sharing professional experience.
• MIT Critical DatacoreStrategic or Co-development Partner · 27 September 2025Co-organizer of Poland Healthcare Datathon 2025 with Roche Polska, GUMed, and UCK Gdańsk. MIT Critical Data provides international scientific oversight and expert participation (dr Leo Celi from MIT as keynote speaker). The partnership drives AI evaluation in Polish medical context using real clinical data.
• Gdański Uniwersytet Medyczny (Medical University of Gdańsk)coreStrategic or Co-development Partner · 27 September 2025Co-organizer of Poland Healthcare Datathon 2025. Provided academic expertise, international expert speakers, and student participants from 14 universities. Dr hab. Jakub Mieczkowski contributed to project oversight.
• Uniwersyteckie Centrum Kliniczne w Gdańsku (UCK)coreStrategic or Co-development Partner · 27 September 2025Co-organizer and host venue of Poland Healthcare Datathon 2025. Provided anonymized real Polish clinical data for LLM evaluation — a first in Poland. Dariusz Szplit (Head of Innovation) oversaw the initiative. The hospital serves as a model for digital transformation in Polish healthcare.
• Wydawnictwo PZWL (PZWL Publishing House)secondaryTechnology or Integration · 1 January 2025Partner of Poland Healthcare Datathon 2025, providing the Medico PZWL LLM model for evaluation during the hackathon programming challenge on Polish-language clinical data.
• Emory UniversitysecondaryStrategic or Co-development Partner · 1 January 2025Supporting institution for Poland Healthcare Datathon 2025. Dr Judy Gichoya (Emory) participated as international expert speaker.
• Google ResearchsecondaryTechnology or Integration · 1 January 2025Supporting institution for Poland Healthcare Datathon 2025. Dr Stephen Pfohl (Google Research) participated as international expert speaker on AI in healthcare.
• Politechnika Gdańska (Gdańsk University of Technology)secondaryStrategic or Co-development Partner · 1 January 2025Supporting institution for Poland Healthcare Datathon 2025. Prof. Jacek Rumiński from the university participated as expert speaker.
• Politechnika Poznańska (Poznań University of Technology)secondaryStrategic or Co-development Partner · 1 January 2025Supporting institution for Poland Healthcare Datathon 2025. Prof. Krzysztof Krawiec participated as expert speaker.
• Human Centred Design Sub-Chapter and InnoLabminorStrategic or Co-development Partner · 1 January 2025Organized Accessify IT event — 'Accelerate Together, Include Everyone!' — focused on accessible technology and inclusive design in healthcare innovation.
• Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu (Poznań Medical University)coreStrategic or Co-development Partner · 1 January 2022Co-creator and partner of 'Data Science w Medycynie' (Data Science in Medicine) postgraduate program, initiated in 2022. Roche Polska co-developed curriculum covering Python, ML/DL, NLP, Computer Vision, and clinical data projects. The program received ~3.5M PLN grant from Medical Research Agency (2nd place in national competition ABM/2023/6). The 2024 edition had 29 graduates; 2026 edition started with 30 students from 130 applicants.
• Inkubator Uniwersytetu Warszawskiego (University of Warsaw Incubator)secondaryStrategic or Co-development Partner · 1 January 2017Since 2017, Roche Polska collaborates with UW Incubator to nurture future business and science leaders in technology and biomedicine. Joint initiatives include BioMed Leaders Academy (3rd edition in 2019 with 60 applicants, 20 laureates) and InnoHub program focusing on senior care innovation.
• Centrum Onkologii-Instytut im. Marii Skłodowskiej CuriecoreStrategic or Co-development Partner · 1 January 2016Co-founded Centrum Naukowo-Przemysłowe (Science-Industry Center) in 2016 — the first early-phase oncology clinical trials center in Poland. Estimated annual value of trials conducted: 10 million PLN. Enables Polish patients to access Phase I-II trials domestically and supports patent protection for new molecular entities.

Scale indicators17 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bayer Poland: Bayer Poland operates as a direct competitor in specialty pharmaceuticals, with significant overlap in oncology, women's health, and cardiology. Both companies leverage similar medical-representative-driven go-to-market models in the Polish hospital and specialty care market.
• Johnson & Johnson Poland (Innovative Medicine): Johnson & Johnson Poland's Innovative Medicine division is a direct competitor in oncology, hematology, and specialty care. Both companies compete in the same Polish hospital specialty care market and overlap significantly in clinical trial portfolio allocation across Polish academic centers.
• MSD Poland (Merck & Co.): MSD Poland is the Polish subsidiary of Merck & Co., a direct competitor in oncology, vaccines, and innovative pharmaceuticals. Both companies compete for the same oncology clinical trial footprint in Poland and engage with similar hospital and oncology center partnerships.
• Sanofi Poland: Sanofi Poland operates as a direct competitor in specialty pharmaceuticals, including rare diseases, oncology, and immunology. Both companies serve the same Polish healthcare ecosystem with similar go-to-market models through medical representatives and hospital-based clinical engagement.
• Boehringer Ingelheim Poland: Boehringer Ingelheim Poland operates as a direct peer in specialty pharmaceuticals, with focus on respiratory, cardiometabolic, and specialty care areas. Both companies compete for the same Polish healthcare professional relationships and specialty care reimbursement listings.
• AstraZeneca Poland: AstraZeneca Poland operates as a direct competitor in oncology, respiratory, and cardiovascular innovative medicines within the Polish market. Both companies compete for oncology market share and clinical trial center partnerships across Polish hospital systems, with similar profiles in late-stage pipeline launches.
• Novartis Poland: Novartis Poland is the Polish subsidiary of Swiss multinational Novartis, operating as a direct competitor in innovative pharmaceuticals with strong oncology, neurology, and specialty care portfolios. Both companies compete head-to-head for Polish reimbursement listings and clinical trial allocation, with similar Swiss-pharma heritage and therapeutic area focus.
• GSK Poland: GSK Poland operates as a direct peer in specialty pharmaceuticals, vaccines, and HIV, with comparable portfolio breadth and similar engagement with Polish healthcare professionals. Both companies compete in clinical trial recruitment and reimbursement negotiations across Polish hospital systems.
• Pfizer Poland: Pfizer Poland is the Polish subsidiary of the US multinational, operating as a direct peer across innovative pharmaceuticals including oncology, vaccines, and specialty care. Both companies compete for the same Polish healthcare professional relationships, hospital formularies, and clinical trial site partnerships.
• Eli Lilly Poland: Eli Lilly Poland operates as a direct competitor in innovative pharmaceuticals, with significant overlap in oncology, diabetes, and neurology. Both companies compete for Polish clinical trial allocation and specialty physician relationships across the same hospital ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/RochePolska
• YouTubeyoutube.com/watch?v=aO4h3BDdD-s&list=PLmXzuVn0p6GBAP_xWwdVnrLEVicYZSzBH&index=19
• Facebookfacebook.com/roche
• LinkedInlinkedin.com/company/undefined
• Instagraminstagram.com/roche

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche Polska